Comparing two imaging tests for high-risk neuroblastoma
Part of Cancer clinical trials.
This trial compares two imaging scans (123I-MIBG and 18F-MFBG) in children with newly diagnosed, high-risk neuroblastoma. The goal is to see if one scan works better to find tumors and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed, high-risk neuroblastoma (a type of nerve cell cancer).
- You must have tumor cells that can be seen on a scan or in a bone marrow sample.
- You cannot be pregnant or breastfeeding, and you must agree to use birth control if needed.
- Most medicines that interfere with the scans (like certain antidepressants or blood pressure drugs) must be stopped temporarily.
- You cannot have a known allergy to the imaging agents (123I-MIBG or 18F-MFBG).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial tests a new PET scan tracer (18F-MFBG) against the standard SPECT scan (123I-MIBG) to see if it better shows neuroblastoma tumors. It's for children whose cancer has come back or hasn't responded to treatment.
This trial compares two different nuclear medicine scans to see which one best shows where neuroblastoma is in a child’s body. The results may help doctors choose the most helpful scan for planning care.
Hear when a new Ganglioneuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.